Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B

Fineline Cube Dec 18, 2025
Company Deals

Sirnaomics Partners on $42M Small Nucleic Acid Fund in Hangzhou

Fineline Cube Dec 18, 2025
Company Deals

HBM BMS Multi-Specific Antibody Deal Targets $1 Billion Milestones

Fineline Cube Dec 18, 2025
Company Deals

Sanofi Adel Alzheimer’s Deal Targets Phase 1 ADEL-Y01 Antibody

Fineline Cube Dec 18, 2025
Company Deals

Byterna Therapeutics Raises Angel Plus Round for cmRNA CAR‑T Pipeline

Fineline Cube Dec 17, 2025
Policy / Regulatory

China Mandates Specialty Departments in Primary Care by 2030

Fineline Cube Dec 18, 2025
Company Drug

Asieris’ APL-2401 FGFR2/3 Inhibitor Wins NMPA Nod for Phase 1 Solid Tumor Trial

Fineline Cube Dec 18, 2025
Company Drug

InnoCare’s Soficitinib Wins NMPA Approval for Phase 2/3 TYK2 Urticaria Study

Fineline Cube Dec 18, 2025
Company

Gritgen Therapeutics Secures Hundreds of Millions in A-Round Financing for Gene Therapy Pipeline

Fineline Cube Mar 2, 2022

Gritgen Therapeutics, a leading gene therapy drug developer based in Suzhou, has announced the successful...

Company Deals

Shenzhen-Based Pregbio Raises Funds for Non-Invasive Prenatal Gene Detection

Fineline Cube Feb 20, 2022

Pregbio, a Shenzhen-based non-invasive prenatal gene detection company, has reportedly raised an undisclosed amount of...

Company

Novartis Cuts Back on US Development of BeiGene’s PD-1 Inhibitor Tislelizumab

Fineline Cube Feb 2, 2022

Novartis AG (NYSE: NVS), BeiGene’s partner, revealed in its Q3 2022 earnings report that it...

Company Drug

Bayer Initiates US Recall of TRK Inhibitor Vitrakvi Due to Mold Contamination

Fineline Cube Nov 21, 2021

Germany-based Bayer (ETR: BAYN) has announced a voluntary recall of a specific lot of its...

Company Drug

Novartis’ Tislelizumab Faces FDA Hurdle in First-Line NSCLC Monotherapy

Fineline Cube Jul 21, 2021

Novartis disclosed during its Q2 2022 earnings call that the U.S. FDA deemed clinical data...

Company Drug

Latin America Accelerates COVID-19 Fight with Vaccine and Treatment Initiatives Across the Region

Fineline Cube Aug 7, 2020

Latin America is ramping up its contributions to the worldwide race for COVID-19 vaccines and...

Company

Exegenesis Bio Secures Multi-Million Dollar Series B Financing for Gene Therapy Pipeline

Fineline Cube Aug 4, 2020

Exegenesis Bio Inc., a leading gene therapy company, has successfully completed a Series B financing...

Company Drug

Genscript’s CAR-T Therapy JNJ-4528 Demonstrates 100% Effective Rate in Long-Term Myeloma Study

Fineline Cube May 14, 2020

Genscript Biotech Corporation (HKG: 1548), a leading China-based Contract Development and Manufacturing Organization (CDMO), has...

Company Deals

Asymchem Laboratories Secures RMB 2.31 Billion Private Placement with Hill House Capital Subscription

Fineline Cube May 14, 2020

Asymchem Laboratories (Tianjin) Co., Ltd, a renowned Contract Development and Manufacturing Organization (CDMO) based in...

Company Drug

Innovent Biologics and Eli Lilly & Co.’s Tyvyt Achieves Primary Endpoints in Phase II ESCC Clinical Study

Fineline Cube May 14, 2020

Innovent Biologics (HKG: 1801), a prominent biotech firm headquartered in Suzhou, China, and Eli Lilly...

Company Deals

Luye Pharma Expands Latin American Reach with Exclusive Seroquel Promotion Agreement in Brazil and Mexico

Fineline Cube May 14, 2020

Luye Pharma Group (HKG: 2186), a leading Chinese pharmaceutical conglomerate, has declared that its wholly-owned...

Company Drug

Zai Lab’s Optune Approved by China’s NMPA, Offering New Hope for Glioblastoma Patients

Fineline Cube May 14, 2020

Zai Lab Ltd (NASDAQ: ZLAB), a biopharmaceutical company based in China, has received approval from...

Policy / Regulatory

Enhancing Clinical Trial Success: CDE’s New Adaptive Design Framework Opens for Comment

Fineline Cube May 14, 2020

The newly proposed guidelines are designed to be applicable across a spectrum of confirmatory clinical...

Company

Thermo Fisher Scientific Develops Serology Test to Detect COVID-19 Antibodies in Collaboration with WuXi Diagnostics and Mayo Clinic

Fineline Cube May 14, 2020

Thermo Fisher Scientific Inc., a titan in the US device industry and listed on the...

Company

Cuban-Chinese Pharma Synergy: Joint R&D and Sales Initiative Targets USD 24.53 Billion in Sales

Fineline Cube May 14, 2020

In a significant move to bolster its innovation pipeline, Guangzhou Pharmaceutical Holdings Ltd. has entered...

Deals

Guangzhou Pharma and BioCubaFarma Chart New Course with Joint Biologics R&D and Exchange Deal

Fineline Cube May 14, 2020

Guangzhou Pharmaceutical Holdings Ltd., a prominent player in China’s pharmaceutical sector, has inked a strategic...

Company Drug

Hanx Biopharmaceuticals’ HX009 Receives NMPA Clinical Trial Approval for PD-1/CD47 Bispecific Antibody

Fineline Cube Nov 4, 2019

China-based Hanx Biopharmaceuticals Co., Ltd has announced that its self-developed anti PD-1/CD47 bispecific antibody drug,...

Company

LanssonPharm Secures Series A Funding to Accelerate CNS Drug Development

Fineline Cube Jan 28, 2019

LanssonPharm, a company dedicated to the development of central nervous system (CNS) drugs, has announced...

Hospital

China’s Ministry of Health Tightens Organ Transplant Regulations with Expert Conference

Fineline Cube Apr 4, 2007

Shi Bingyi, a distinguished Member of the National Committee of the CPPCC (Chinese People’s Political...

R&D

China Launches Unprecedented Multi-Center Hypertension Study with Global Implications

Fineline Cube Apr 4, 2007

On April 2nd, a landmark healthcare initiative, the “Hypertension Prevention and Treatment Research” project, commenced...

Posts pagination

1 … 597 598 599

Recent updates

  • Asieris’ APL-2401 FGFR2/3 Inhibitor Wins NMPA Nod for Phase 1 Solid Tumor Trial
  • InnoCare’s Soficitinib Wins NMPA Approval for Phase 2/3 TYK2 Urticaria Study
  • InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B
  • China Mandates Specialty Departments in Primary Care by 2030
  • Sirnaomics Partners on $42M Small Nucleic Acid Fund in Hangzhou
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Asieris’ APL-2401 FGFR2/3 Inhibitor Wins NMPA Nod for Phase 1 Solid Tumor Trial

Company Drug

InnoCare’s Soficitinib Wins NMPA Approval for Phase 2/3 TYK2 Urticaria Study

Company Deals

InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B

Policy / Regulatory

China Mandates Specialty Departments in Primary Care by 2030

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.